11-47333226-AC-ACC
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000256.3(MYBPC3):c.3297dupG(p.Tyr1100ValfsTer49) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. G1099G) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000256.3 frameshift
Scores
Clinical Significance
Conservation
Publications
- hypertrophic cardiomyopathyInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- hypertrophic cardiomyopathy 4Inheritance: AD, AR Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, G2P, Labcorp Genetics (formerly Invitae)
- left ventricular noncompaction 10Inheritance: AR, AD Classification: DEFINITIVE, MODERATE, LIMITED Submitted by: Ambry Genetics
- familial isolated dilated cardiomyopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- arrhythmogenic right ventricular cardiomyopathyInheritance: AD Classification: LIMITED Submitted by: ClinGen
- atrial fibrillationInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- dilated cardiomyopathyInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000256.3. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MYBPC3 | NM_000256.3 | MANE Select | c.3297dupG | p.Tyr1100ValfsTer49 | frameshift | Exon 30 of 35 | NP_000247.2 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| MYBPC3 | ENST00000545968.6 | TSL:5 MANE Select | c.3297dupG | p.Tyr1100ValfsTer49 | frameshift | Exon 30 of 35 | ENSP00000442795.1 | ||
| MYBPC3 | ENST00000399249.6 | TSL:5 | c.3297dupG | p.Tyr1100ValfsTer49 | frameshift | Exon 29 of 34 | ENSP00000382193.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.0000138 AC: 3AN: 216706 AF XY: 0.0000256 show subpopulations
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 0.00000208 AC: 3AN: 1444726Hom.: 0 Cov.: 34 AF XY: 0.00000418 AC XY: 3AN XY: 716926 show subpopulations
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p.Tyr1100ValfsX49 (c. 3297dupG) in the MYBPC3 gene. We classify it as likely disease causing, based on the data reviewed below. The variant was re-reviewed February 17th, 2012. This variant is novel. The addition of Guanine at position 3297 causes a reading frame shift at codon 1100; as a result a premature stop codon is created 49 codons downstream. The amino acid sequence from codon 1100 to 1149 is changed, as well. The variant is expected to either cause a truncated MYBPC3 protein or a completely absent MYBPC3 protein due to nonsense-mediate mRNA decay. While this specific variant is novel, many other frameshift and null variants have been identified in MYBPC3 in association with cardiomyopathy (ex. p.Trp792fs, p.Pro794fs, p.Lys1065fs, p.Cys1202fs, p.Pro1208fs, p.Trp1098ter, p.Glu1096ter, p.Cys1124ter, p.Gln1233ter). The variant has not been seen in a total of 5200 laboratory controls and publicly available general population samples. The variant is not listed in the NHLBI Exome Sequencing Project dataset, which currently includes calls for MYBPC3 on ~5000 Caucasian and African-American individuals. Of note, there are no frameshift variants in that dataset. These if one nonsense variant, but it has been reported previously in association with HCM. There was no control data reported in the results. Upon request, GeneDx verbally provided control data on March 31st, 2011; the variant was not observed in 100 Caucasian control individuals (with high coverage) or 100 African American control individuals (with low coverage).
Hypertrophic cardiomyopathy Pathogenic:2
The Tyr1100fs variant (MYBPC3) has not been reported in the literature but has b een identified in one individual with HCM (this individual's father) by our labo ratory. This frameshift variant is predicted to alter the protein?s amino acid sequence beginning at position 1100 and lead to a premature termination codon 49 amino acids downstream. This alteration is then predicted to lead to a truncate d or absent protein. Heterozygous loss of function of the MYBPC3 gene is an esta blished disease mechanism in HCM, which makes it highly likely that this variant is pathogenic.
This sequence change creates a premature translational stop signal (p.Tyr1100Valfs*49) in the MYBPC3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MYBPC3 are known to be pathogenic (PMID: 19574547). This variant is present in population databases (rs397516014, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 27532257). ClinVar contains an entry for this variant (Variation ID: 42702). For these reasons, this variant has been classified as Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at